NASDAQ:BIOA BioAge Labs (BIOA) Stock Price, News & Analysis $4.77 -0.33 (-6.47%) Closing price 04:00 PM EasternExtended Trading$4.83 +0.06 (+1.26%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioAge Labs Stock (NASDAQ:BIOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioAge Labs alerts:Sign Up Key Stats Today's Range$4.77▼$5.1350-Day Range$4.77▼$8.6552-Week Range$4.77▼$25.95Volume640,566 shsAverage Volume716,440 shsMarket Capitalization$219.23 millionP/E RatioN/ADividend YieldN/APrice Target$29.00Consensus RatingModerate Buy Company Overview BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial. Founded in 2015, BioAge is headquartered in Richmond, California. Co-founder Kristen Fortney, Ph.D., serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More BioAge Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreBIOA MarketRank™: 2.77845117845 of 5 starsBioAge Labs scored higher than 56% of companies evaluated by MarketBeat, and ranked 899th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBioAge Labs has a consensus price target of $29.00, representing about 508.0% upside from its current price of $4.77.Amount of Analyst CoverageBioAge Labs has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioAge Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioAge Labs are expected to grow in the coming year, from ($2.59) to ($2.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAge Labs is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAge Labs is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAge Labs has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.84% of the float of BioAge Labs has been sold short.Short Interest Ratio / Days to CoverBioAge Labs has a short interest ratio ("days to cover") of 4.34.Change versus previous monthShort interest in BioAge Labs has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioAge Labs does not currently pay a dividend.Dividend GrowthBioAge Labs does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.19 News SentimentBioAge Labs has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioAge Labs this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added BioAge Labs to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioAge Labs insiders have not sold or bought any company stock.Percentage Held by Insiders17.55% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBioAge Labs has minimal institutional ownership at this time.Read more about BioAge Labs' insider trading history. Receive BIOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAge Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOA Stock News HeadlinesBioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 16 at 6:54 PM | seekingalpha.comTranscript : BioAge Labs, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 04:40 PMNovember 16 at 1:53 PM | marketscreener.comMYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 18 at 1:00 AM | Behind the Markets (Ad)BTIG Research Reaffirms Buy Rating for BioAge Labs (NASDAQ:BIOA)November 11, 2026 | americanbankingnews.comBioAge Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMBioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 5, 2026 | globenewswire.comDeep Origin Announces Multi-Target Ai-Driven Drug Discovery Collaboration with BioAge Labs, IncOctober 14, 2026 | marketscreener.comMBioAge Labs, Deep Origin Collaborate on AI-Driven Drug DiscoveryOctober 14, 2026 | marketscreener.comMSee More Headlines BIOA Stock Analysis - Frequently Asked Questions How have BIOA shares performed this year? BioAge Labs' stock was trading at $13.23 at the start of the year. Since then, BIOA shares have decreased by 63.9% and is now trading at $4.77. How were BioAge Labs' earnings last quarter? BioAge Labs, Inc. (NASDAQ:BIOA) posted its earnings results on Thursday, November, 5th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.05. The firm earned $298 thousand during the quarter. BioAge Labs had a negative trailing twelve-month return on equity of 31.42% and a negative net margin of 1,253.60%. When did BioAge Labs IPO? BioAge Labs (BIOA) raised $88 million in an initial public offering (IPO) on Friday, May 10th 2013. The company issued 8,000,000 shares at a price of $10.00-$12.00 per share. Who are BioAge Labs' major shareholders? Top institutional shareholders of BioAge Labs include a16z Capital Management L.L.C. (7.03%), State Street Corp (2.93%), Goldman Sachs Group Inc. (0.67%) and Profund Advisors LLC (0.17%). Insiders that own company stock include Kristen Fortney, Dov A Md Goldstein and Paul D Rubin. View institutional ownership trends. How do I buy shares of BioAge Labs? Shares of BIOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioAge Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioAge Labs investors own include Intel (INTC), NVIDIA (NVDA), AbbVie (ABBV), Kinder Morgan (KMI), Sorrento Therapeutics (SRNE), JD.com (JD) and Micron Technology (MU). Company Calendar Last Earnings11/05/2026Today11/18/2026Jefferies Global Healthcare Conference11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BIOA's financial health is in the Red zone, according to TradeSmith. BIOA has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BIOA Previous SymbolNYSE:BIOA CIK1709941 Webbioagelabs.com Phone(510) 806-1445FaxN/AEmployees62Year Founded2015Price Target and Rating Average Price Target for BioAge Labs$29.00 High Price Target$60.00 Low Price Target$8.00 Potential Upside/Downside+508.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.61 million Net Margins-1,253.60% Pretax Margin-1,253.60% Return on Equity-31.42% Return on Assets-29.59% Debt Debt-to-Equity RatioN/A Current Ratio15.51 Quick Ratio15.51 Sales & Book Value Annual Sales$8.99 million Price / Sales24.39 Cash FlowN/A Price / Cash FlowN/A Book Value$7.54 per share Price / Book0.63Miscellaneous Outstanding Shares45,960,000Free Float37,893,000Market Cap$219.23 million OptionableOptionable Beta1.19 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BIOA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAge Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAge Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.